Health Canada issues licences to Fujirebio’s Lumipulse assays

Fujirebio has received Class II Medical Device Licences from Health Canada for its Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays. The licences were issued based on the CE-marked in vitro diagnostic versions of the two assays already available in Europe. The licences allow clinicians and patients in Canada access to the biomarker tests for neurological diseases. Credit: sasirin pamai / Shutterstock.com. HU Group Holdings’ wholly owned subsidiary Fujirebio has received Class II Medical Device Licences from Health Canada for its Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays. These licences allow Fujirebio to…

Source: Medical Device Network